Core Viewpoint - The company reported a revenue of HKD 877 million for the six months ending June 30, 2025, representing a year-on-year increase of 5.8% [1] - The gross profit reached HKD 779 million, showing a year-on-year growth of 5.4% [1] - The profit attributable to the company's owners was HKD 163 million, which is a 3.8% increase compared to the previous year [1] - The basic earnings per share were HKD 0.2882, and the company proposed an interim dividend of HKD 0.07 per ordinary share [1] Financial Performance - Revenue: HKD 877 million, up 5.8% year-on-year [1] - Gross Profit: HKD 779 million, up 5.4% year-on-year [1] - Profit Attributable to Owners: HKD 163 million, up 3.8% year-on-year [1] - Basic Earnings per Share: HKD 0.2882 [1] - Proposed Interim Dividend: HKD 0.07 per ordinary share [1]
亿胜生物科技(01061.HK)：上半年纯利为1.63亿港元 同比增加3.8%